PCI Biotech Holding ASA
PCIB
PCI Biotech Holding ASA, an Oslo, Norway-based biopharmaceutical firm, is... PCI Biotech Holding ASA, an Oslo, Norway-based biopharmaceutical firm, is focused on pioneering and bringing to market innovative treatments for cancer. At the core of their operations is the proprietary photochemical internalization (PCI) technology platform. The company's development pipeline features several distinct therapeutic strategies: fimaCHEM, a novel approach to chemotherapeutic cancer treatment; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is currently in Phase I clinical studies; and fimaNAc, a delivery system for nucleic acid therapeutics, presently in its pre-clinical phase. Furthermore, they provide Amphinex, a photosensitizer known as fimaporfin. PCI Biotech actively participates in joint research endeavors with partners such as Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense.
